| Autor: |
Edinoff AN; Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Science Center Shreveport, Shreveport, LA 71103, USA., Sanders NM; Shreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USA., Lewis KB; Shreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USA., Apgar TL; Department of Chemical Biology and Biochemistry, Vanderbilt University, Nashville, TN 37235, USA., Cornett EM; Department of Anesthesiology, Louisiana State University Health Science Center Shreveport, Shreveport, LA 71103, USA., Kaye AM; Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA., Kaye AD; Department of Anesthesiology, Louisiana State University Health Science Center Shreveport, Shreveport, LA 71103, USA. |
| Abstrakt: |
Hypoactive sexual desire disorder (HSDD) is a persistent deficiency or absence of sexual fantasies and desire resulting in significant distress or interpersonal difficulty. Women with this disorder may display a lack of motivation for sexual activity, reduced responsiveness to erotic cues, a loss of interest during sexual activity, and avoidance of situations that could lead to sexual activity. The pathophysiology of HSDD is thought to be centered around inhibitory and excitatory hormones, neurotransmitters, and specific brain anatomy. Due to the multifactorial nature of HSDD, treatment can be complex and must attempt to target the biological and psychosocial aspects of the disorder. Bremelanotide is a melanocortin receptor agonist and has been recently approved by the FDA to treat HSDD. Bremelanotide is administered intranasally or as a subcutaneous injection. The recommended dosage of bremelanotide is 1.75 mg injected subcutaneously in the abdomen or thigh at least 45 min before sexual activity. Studies showed improvements in desire, arousal, and orgasm scores when 1.75 mg of bremelanotide was administered before sexual activity compared to a placebo. Bremelanotide is a promising way to treat HSDD. |
